Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis
Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ. 2013 Nov 5;185(16):1393-401. doi: 10.1503/cmaj.130451.
[sidebar]
Commissioned and Funded by: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
[/no-bottom-margin]
Share Buttons [span][/span]
[ssba-buttons] [/sidebar] [sidebar-content]- Influenced the decision to continue delisting cognitive enhancers for mild cognitive impairment
- Informed the Canadian Task Force on Preventive Healthcare guidelines on screening for cognitive impairment in older adults
- Featured in >150 mass media articles
- Patients taking cognitive enhancers experienced significantly more nausea, diarrhea, vomiting, and headaches compared to those on placebo. There were no differences in major adverse events between those taking cognitive enhancers and placebo. No improvements in cognition, function or mortality were identified among patients who used cognitive enhancers
Altmetrics:
Related Projects:
[/sidebar-content]Category : KS Projects
Date : 12 Aug 2020